233 related articles for article (PubMed ID: 19397688)
1. Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
Balakrishnan VS; Rao M; Kausz AT; Brenner L; Pereira BJ; Frigo TB; Lewis JM
Eur J Clin Invest; 2009 Jun; 39(6):489-96. PubMed ID: 19397688
[TBL] [Abstract][Full Text] [Related]
2. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
3. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
Connor JR; Zhang X; Nixon AM; Webb B; Perno JR
PLoS One; 2015; 10(5):e0125272. PubMed ID: 25973894
[TBL] [Abstract][Full Text] [Related]
6. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
Hempel JC; Poppelaars F; Gaya da Costa M; Franssen CF; de Vlaam TP; Daha MR; Berger SP; Seelen MA; Gaillard CA
Am J Nephrol; 2017; 45(1):49-59. PubMed ID: 27889746
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ferumoxytol versus sodium ferric gluconate in anemia management in outpatient hemodialysis patients: A prospective cohort study.
El Nekidy WS; El-Masri MM; Kadri A; Soong DC
Clin Nephrol; 2021 Apr; 95(4):189-194. PubMed ID: 33433318
[TBL] [Abstract][Full Text] [Related]
8. The available intravenous iron formulations: History, efficacy, and toxicology.
Auerbach M; Macdougall I
Hemodial Int; 2017 Jun; 21 Suppl 1():S83-S92. PubMed ID: 28371203
[TBL] [Abstract][Full Text] [Related]
9. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
10. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.
Schwenk MH
Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475
[TBL] [Abstract][Full Text] [Related]
11. Ferumoxytol for the treatment of iron deficiency anemia.
Auerbach M; Chertow GM; Rosner M
Expert Rev Hematol; 2018 Oct; 11(10):829-834. PubMed ID: 30188740
[TBL] [Abstract][Full Text] [Related]
12. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
Kowalczyk M; Banach M; Rysz J
J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
[TBL] [Abstract][Full Text] [Related]
13. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
Potthoff SA; Münch HG
Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron infusion and newer non-dextran formulations.
Aung T; Coleman J; Davidson PW; Hetzel DJ; Aung ST
N Z Med J; 2021 Apr; 134(1534):118-127. PubMed ID: 33927444
[TBL] [Abstract][Full Text] [Related]
15. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
16. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients.
Airy M; Mandayam S; Mitani AA; Chang TI; Ding VY; Brookhart MA; Goldstein BA; Winkelmayer WC
Nephrol Dial Transplant; 2015 Dec; 30(12):2068-75. PubMed ID: 26311216
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
18. Oxidative effect of several intravenous iron complexes in the rat.
Bailie GR; Schuler C; Leggett RE; Li H; Li HD; Patadia H; Levin R
Biometals; 2013 Jun; 26(3):473-8. PubMed ID: 23681275
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).
Neiser S; Koskenkorva TS; Schwarz K; Wilhelm M; Burckhardt S
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27455240
[TBL] [Abstract][Full Text] [Related]
20. Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.
Wetmore JB; Weinhandl ED; Zhou J; Gilbertson DT
PLoS One; 2017; 12(1):e0171098. PubMed ID: 28135334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
